Surprising specificity of LY294002 in inhibiting IL-6 but not TRAF-1 expression is encouraging as inhibitors with similar properties can be used to reduce invasion of breast cancer cells, more so of ERα-positive cancer cells, by specifically reducing IL-6 expression. Here, TRAF1 is linked to cancer.